Whether the 3 new biologics for asthma will be listed for insurance reimbursement in Korea is receiving attention.

According to industry sources, treatments for severe asthma including GSK Korea’s Nucala (mepolizumab), Teva-Handok’s Cinqair (reslizumab), and AstraZeneca Korea’s Fasenra (benralizumab) are undergoing processes for reimbursement in Korea.

As interleukin-5 antagonists, the drugs reduce levels of blood eosinophils, a type of white blood cell that is involved in the development of asthma exacerbation. At the time of their approval, the drugs received attention for being an effective treatment option that had not been available before.

All 3 drugs have been a